Rexam Healthcare Expands Manufacturing for Drug Delivery Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Rexam Healthcare Expands Manufacturing for Drug Delivery Systems


Rexam Healthcare, a subsidiary of the UK group Rexam, will expand manufacturing capabilities at its French site in Le Tréport, Seine Maritime, the company announced in a press release.

This site specializes in drug delivery systems, including the recently introduced Advancia pump for the nasal-spray sector. The plant expansion and the Advancia project, which is supported by the European Regional Development Fund in Normandy, will add approximately fifty jobs.
 
Along with other site improvements, the manufacturing expansion will include a production building with a 2900-square meter cleanroom and 1500 square meters housing the machine and mold maintenance workshops, metrology unit, laboratory, and administrative premises. The cleanroom is expected to open in November 2013 and full inauguration of the site is expected in early 2014.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here